跳至主要内容
临床试验/NCT07510698
NCT07510698招募中不适用

Evaluation of Safety, Quality of Life, Cost and Environmental Impact of Day Surgery in Mastectomy and Prepectoral Reconstruction - Awake MAstectomy in Day Surgery With Immediate Prepectoral Implant Reconstruction and Muscle Sparing

University of Rome Tor Vergata1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Postoperative pain at rest over 48 hours

研究概览

简要总结

The goal of this clinical trial is to learn if the AMADeuS care pathway is as safe as usual hospital care and works as well for pain control in women having mastectomy with immediate prepectoral breast reconstruction. The study will also look at quality of life, satisfaction with care, hospital resource use, and environmental impact.

The main questions it aims to answer are:

  1. Does the AMADeuS pathway control pain during the first 48 hours after surgery as well as usual hospital care?
  2. Is the AMADeuS pathway as safe as usual hospital care during the first 30 days after surgery?
  3. Can the AMADeuS pathway improve recovery, reduce hospital stay and hospital visits, and lower the environmental impact of care?

Researchers will compare the AMADeuS pathway with usual hospital care. In the AMADeuS pathway, participants will have awake surgery with monitored anesthesia care, same-day discharge when safe, and follow-up that includes telemedicine. In the usual care group, participants will receive the hospital's standard perioperative care, which usually includes admission to the ward and follow-up visits at the hospital.

Participants may be women 18 to 75 years old who need nipple-sparing or skin-sparing mastectomy with immediate prepectoral reconstruction for early breast cancer or to lower future breast cancer risk. Participants must be suitable for day surgery and telemedicine follow-up. This includes having home support during the first 24 hours after surgery and living close enough to the hospital for safe discharge.

Participants will:

  • be assigned by chance to the AMADeuS pathway or to usual hospital care have mastectomy with immediate prepectoral reconstruction report their pain during the first 48 hours after surgery
  • be checked for medical problems during the first 30 days after surgery complete questionnaires about quality of life, symptoms, and satisfaction with care during follow-up
  • have follow-up visits either through telemedicine and planned local care support or through standard hospital follow-up, depending on the group they are assigned to

详细描述

Breast cancer remains one of the most common indications for mastectomy, despite the increasing use of breast-conserving approaches in selected patients. In current practice, nipple-sparing mastectomy and skin-sparing mastectomy followed by immediate implant-based reconstruction aim to maintain oncologic safety while improving aesthetic, functional, and psychosocial outcomes. Within implant-based reconstruction, the prepectoral approach avoids elevation of the pectoralis major muscle and may reduce muscle-related morbidity, postoperative pain, and animation deformity in appropriately selected participants.

Perioperative breast surgery pathways are also evolving toward higher-value care models based on enhanced recovery after surgery, opioid-sparing anesthesia, day surgery, and structured remote follow-up. Existing evidence supporting same-day discharge after mastectomy with immediate reconstruction suggests that this approach can be feasible and safe in selected patients when perioperative criteria and post-discharge support are standardized. In parallel, healthcare systems are increasingly required to consider resource use and environmental impact in addition to conventional clinical outcomes.

The AMADeuS protocol (Awake MAstectomy in Day surgery with immediate prepectoral implant reconstruction and muscle Sparing) was developed to integrate these elements into a single perioperative pathway for patients undergoing nipple-sparing or skin-sparing mastectomy with immediate prepectoral prosthetic reconstruction. The study is a prospective randomized single-center trial comparing the AMADeuS pathway with the institution's standard perioperative management. Its overall aim is to determine whether this integrated pathway can maintain clinical safety and adequate postoperative pain control while improving recovery, reducing hospital resource use, and lowering the environmental burden of care.

In the experimental arm, the AMADeuS pathway combines outpatient-oriented pre-admission planning, enhanced recovery principles, awake monitored anesthesia care with local anesthesia and interfascial locoregional blocks when appropriate, multimodal opioid-sparing analgesia, same-day discharge when discharge criteria are met, and structured telemedicine-supported follow-up. Preoperative management includes reduced fasting, carbohydrate loading, and risk-adapted thromboprophylaxis. Intraoperative management includes systematic antiemetic prophylaxis, targeted oxygen delivery, and minimization of unnecessary drug and material use according to a "do not open unless needed" approach. The operating room workflow is also organized to reduce waste through modular instrument sets opened only if required, reduced use of disposable devices, monitoring of personnel present in the room, and segregation of waste into predefined categories for environmental assessment. Postoperatively, the pathway promotes early oral intake, early mobilization, short ambulatory observation, same-day discharge when clinically appropriate, telemedicine review at 7 days, and suture removal either in clinic or through local primary care support.

In the control arm, participants undergo the same underlying surgical indication and reconstructive strategy within the hospital's usual care pathway. Standard care includes inpatient admission, perioperative management according to routine anesthetic and surgical practice, postoperative ward stay, and in-person postoperative follow-up. In this arm, anesthesia technique, airway management, instrument preparation, and operating room waste handling are left to standard institutional practice and clinician preference rather than protocolized sustainability measures.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

This is an open-label trial for participants and treating clinicians because the study compares 2 different perioperative care pathways. An independent blinded outcome assessor will review prespecified postoperative clinical outcomes, including 30-day complications, whenever feasible.

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • **Inclusion Criteria:**
  • Biologically female participants aged 18 to 75 years
  • Oncologic or prophylactic indication for nipple-sparing mastectomy or skin-sparing mastectomy with immediate prepectoral reconstruction using a definitive implant or tissue expander, including early breast cancer or a high-risk genetic condition such as BRCA
  • Eligible for prepectoral reconstruction based on clinico-anatomic criteria, including adequate skin flap thickness, no relevant vascular compromise, body mass index less than 35, and no severe prior chest radiotherapy
  • American Society of Anesthesiologists (ASA) class I to III
  • Eligible for day surgery, defined by home autonomy, caregiver availability during the first 24 hours after surgery, and distance from the hospital compatible with home management
  • Able and willing to complete telemedicine follow-up, including completion of protocol-required patient-reported outcome measures
  • Written informed consent provided

排除标准

  • Chronic opioid use or treatment for pre-existing chronic pain that could interfere with assessment of the primary postoperative pain endpoint
  • Contraindications to locoregional anesthesia techniques or to the awake/monitored anesthesia care protocol, including allergy to local anesthetics, coagulation disorders, or inability to cooperate during surgery
  • Body mass index 35 or greater, or anatomic conditions contraindicating prepectoral reconstruction
  • Previous high-dose chest radiotherapy with significant tissue compromise
  • Pregnancy or breastfeeding
  • Inability to guarantee planned follow-up or lack of adequate home support
  • Psychiatric or cognitive conditions preventing correct completion of patient-reported outcome measures

研究组 & 干预措施

AMADeuS Pathway

Experimental

Participants assigned to this arm undergo nipple-sparing or skin-sparing mastectomy with immediate prepectoral implant-based reconstruction within the AMADeuS perioperative pathway. This pathway includes awake monitored anesthesia care with local anesthesia and interfascial locoregional blocks when appropriate, multimodal opioid-sparing analgesia, enhanced recovery measures, same-day discharge when discharge criteria are met, telemedicine-supported follow-up, and sustainability-oriented operating room practices.

干预措施: AMADeuS Perioperative Pathway (Other)

Usual Care Pathway

Active Comparator

Participants assigned to this arm undergo nipple-sparing or skin-sparing mastectomy with immediate prepectoral implant-based reconstruction within the institution's standard perioperative care pathway. Usual care includes inpatient admission, perioperative anesthetic and surgical management according to routine clinical practice, postoperative ward stay, discharge in the following days as clinically indicated, and standard in-person hospital follow-up.

干预措施: Usual Perioperative Care (Other)

结局指标

主要结局

Postoperative pain at rest over 48 hours

时间窗: 0 to 48 hours after surgery

Pain control will be assessed as the area under the curve (AUC) for Numeric Pain Rating Scale (NPRS, 0-10) pain at rest measured at 0, 2, 24, and 48 hours after surgery. Lower values indicate less postoperative pain. The primary analysis is based on non-inferiority of the AMADeuS pathway versus usual care.

Major Postoperative Safety Composite at 30 days

时间窗: Within 30 days after surgery

Composite rate of major postoperative safety events within 30 days, including Clavien-Dindo grade III or higher complications, unplanned reoperation, unplanned hospital readmission, or procedure-related emergency department access.

次要结局

  • Time to mobilization(Within 48 hours after surgery)
  • Carbon footprint from hospitalization(Within 30 days after surgery)
  • Postoperative pain during movement over 48 hours(0 to 48 hours after surgery)
  • Maximum postoperative pain over 48 hours(0 to 48 hours after surgery)
  • Rescue analgesic use over 48 hours(0 to 48 hours after surgery)
  • Postoperative nausea and vomiting over 48 hours(0 to 48 hours after surgery)
  • Same-day discharge rate(Day of surgery)
  • Length of hospital stay(Within 30 days after surgery)
  • Chronic postsurgical pain at 3 months(3 months after surgery)
  • Chronic postsurgical pain at 6 months(6 months after surgery)
  • Global health-related quality of life(Baseline, 1 month, 3 months, 6 months, and 12 months)
  • Breast cancer-specific quality of life(Baseline, 1 month, 3 months, 6 months, and 12 months)
  • Care pathway utilization(From surgery through 12 months after surgery)
  • Reconstruction-related satisfaction and well-being(Baseline, 1 month, 3 months, 6 months, and 12 months)
  • General health status(Baseline, 1 month, 3 months, 6 months, and 12 months)
  • Operating room resource use(During surgery)
  • Satisfaction with care(Baseline, 1 month, 3 months, 6 months, and 12 months)
  • Telemedicine satisfaction(1 month, 3 months, 6 months, and 12 months)
  • Carbon footprint from waste generation(From Admission to surgical room, until hospital discharge)
  • Carbon footprint from transport(From surgery through 30 days after surgery)

研究者

发起方
University of Rome Tor Vergata
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gianluca Vanni

Associate Professor

University of Rome Tor Vergata

研究点 (1)

Loading locations...

相似试验

Same-Day Awake Mastectomy With Immediate Breast... | 临床试验